Loading...

Canopy Growth

TSX:WEED
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
WEED
TSX
CA$20B
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. The last earnings update was 8 days ago. More info.


Add to Portfolio Compare Print
  • Canopy Growth has significant price volatility in the past 3 months.
WEED Share Price and Events
7 Day Returns
-5.4%
TSX:WEED
-0.6%
CA Pharmaceuticals
2.2%
CA Market
1 Year Returns
113%
TSX:WEED
-8.1%
CA Pharmaceuticals
0.5%
CA Market
WEED Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Canopy Growth (WEED) -5.4% 2.2% 33.9% 113% 1948.6% -
CA Pharmaceuticals -0.6% 9.5% 19.7% -8.1% 887.4% -30.3%
CA Market 2.2% 4.5% 5.4% 0.5% 24% 6.1%
1 Year Return vs Industry and Market
  • WEED outperformed the Pharmaceuticals industry which returned -8.1% over the past year.
  • WEED outperformed the Market in Canada which returned 0.5% over the past year.
Price Volatility
WEED
Industry
5yr Volatility vs Market

WEED Value

 Is Canopy Growth undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Canopy Growth. This is due to cash flow or dividend data being unavailable. The share price is CA$59.41.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Canopy Growth's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Canopy Growth's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSX:WEED PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CAD CA$-1.79
TSX:WEED Share Price ** TSX (2019-02-21) in CAD CA$59.41
Canada Pharmaceuticals Industry PE Ratio Median Figure of 15 Publicly-Listed Pharmaceuticals Companies 21.51x
Canada Market PE Ratio Median Figure of 552 Publicly-Listed Companies 14.82x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Canopy Growth.

TSX:WEED PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:WEED Share Price ÷ EPS (both in CAD)

= 59.41 ÷ -1.79

-33.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Canopy Growth is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Canopy Growth is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Canopy Growth's expected growth come at a high price?
Raw Data
TSX:WEED PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -33.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts
96.9%per year
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 10 Publicly-Listed Pharmaceuticals Companies 0.9x
Canada Market PEG Ratio Median Figure of 257 Publicly-Listed Companies 0.94x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Canopy Growth, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Canopy Growth's assets?
Raw Data
TSX:WEED PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CAD CA$21.07
TSX:WEED Share Price * TSX (2019-02-21) in CAD CA$59.41
Canada Pharmaceuticals Industry PB Ratio Median Figure of 120 Publicly-Listed Pharmaceuticals Companies 3.25x
Canada Market PB Ratio Median Figure of 2,330 Publicly-Listed Companies 1.55x
TSX:WEED PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:WEED Share Price ÷ Book Value per Share (both in CAD)

= 59.41 ÷ 21.07

2.82x

* Primary Listing of Canopy Growth.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Canopy Growth is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Canopy Growth's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Canopy Growth has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

WEED Future Performance

 How is Canopy Growth expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
96.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Canopy Growth expected to grow at an attractive rate?
  • Canopy Growth's earnings growth is expected to exceed the low risk savings rate of 1.9%.
Growth vs Market Checks
  • Canopy Growth's earnings growth is expected to exceed the Canada market average.
  • Canopy Growth's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
TSX:WEED Future Growth Rates Data Sources
Data Point Source Value (per year)
TSX:WEED Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts 96.9%
TSX:WEED Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 11 Analysts 47.4%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 85.8%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 49.2%
Canada Market Earnings Growth Rate Market Cap Weighted Average 18%
Canada Market Revenue Growth Rate Market Cap Weighted Average 6.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSX:WEED Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSX:WEED Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-03-31 2,408 1
2022-03-31 1,743 2
2021-03-31 1,343 189 7
2020-03-31 813 -142 10
2019-03-31 242 -415 -427 11
TSX:WEED Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-12-31 155 -332 -411
2018-09-30 94 -257 -477
2018-06-30 88 -137 -142
2018-03-31 78 -82 -70
2017-12-31 70 -60 -21
2017-09-30 58 -41 -19
2017-06-30 49 -36 -13
2017-03-31 40 -27 -8
2016-12-31 30 -14 -1
2016-09-30 24 -16 -7
2016-06-30 18 -14 -8
2016-03-31 13 -14 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Canopy Growth's earnings are expected to grow significantly at over 20% yearly.
  • Canopy Growth's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSX:WEED Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below

All data from Canopy Growth Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSX:WEED Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-03-31
2022-03-31
2021-03-31 0.33 0.35 0.31 2.00
2020-03-31 -0.43 -0.29 -0.60 4.00
2019-03-31 -1.65 -0.71 -2.36 4.00
TSX:WEED Past Financials Data
Date (Data in CAD Millions) EPS *
2018-12-31 -1.79
2018-09-30 -2.39
2018-06-30 -0.76
2018-03-31 -0.40
2017-12-31 -0.13
2017-09-30 -0.13
2017-06-30 -0.09
2017-03-31 -0.06
2016-12-31 -0.01
2016-09-30 -0.07
2016-06-30 -0.09
2016-03-31 -0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Canopy Growth is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Canopy Growth's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Canopy Growth has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

WEED Past Performance

  How has Canopy Growth performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Canopy Growth's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Canopy Growth does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Canopy Growth's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Canopy Growth's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Canopy Growth's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Canopy Growth Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSX:WEED Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 155.10 -411.38 445.62 8.50
2018-09-30 93.75 -477.37 329.07 3.53
2018-06-30 87.99 -141.58 180.24 2.08
2018-03-31 77.95 -70.35 131.13 1.45
2017-12-31 69.80 -20.80 94.76 0.38
2017-09-30 57.86 -19.39 65.74 0.53
2017-06-30 48.78 -12.63 50.47 0.54
2017-03-31 39.90 -7.52 38.55 0.81
2016-12-31 30.28 -0.65 29.47 1.63
2016-09-30 24.01 -6.96 24.65 1.38
2016-06-30 17.97 -8.46 20.53 1.09
2016-03-31 12.70 -3.50 17.33 0.72
2015-12-31 8.41 0.32 12.83 0.49
2015-09-30 5.57 1.00 11.00 0.34
2015-06-30 3.42 -5.30 9.72 0.19
2015-03-31 1.90 -7.48 8.10 0.21
2014-12-31 1.15 -8.93 6.99 0.16
2014-09-30 0.50 -7.07 5.32 0.12
2013-12-31 -0.93 0.93

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Canopy Growth has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Canopy Growth has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Canopy Growth improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Canopy Growth's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Canopy Growth has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

WEED Health

 How is Canopy Growth's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Canopy Growth's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Canopy Growth is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Canopy Growth's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Canopy Growth's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Canopy Growth Company Filings, last reported 1 month ago.

TSX:WEED Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 7,423.68 791.50 4,933.50
2018-09-30 1,840.82 910.16 448.16
2018-06-30 1,224.46 620.29 657.90
2018-03-31 1,243.24 8.42 322.56
2017-12-31 1,019.86 8.79 237.71
2017-09-30 731.57 9.58 108.21
2017-06-30 682.86 9.91 115.49
2017-03-31 639.73 10.33 101.80
2016-12-31 251.52 7.17 92.50
2016-09-30 171.62 7.44 45.38
2016-06-30 132.38 4.13 19.53
2016-03-31 123.79 4.02 15.40
2015-12-31 132.05 3.97 19.72
2015-09-30 112.27 5.90 7.73
2015-06-30 42.92 1.89 15.17
2015-03-31 41.41 1.92 21.45
2014-12-31 21.67 1.88 5.77
2014-09-30 23.18 0.00 8.36
2013-12-31 3.83 0.04 2.09
  • Canopy Growth's level of debt (10.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (1% vs 10.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Canopy Growth has sufficient cash runway for more than 3 years based on current free cash flow.
  • Canopy Growth has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 115.4% each year.
X
Financial health checks
We assess Canopy Growth's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Canopy Growth has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

WEED Dividends

 What is Canopy Growth's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Canopy Growth dividends.
If you bought CA$2,000 of Canopy Growth shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Canopy Growth's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Canopy Growth's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSX:WEED Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
Canada Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

TSX:WEED Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2023-03-31
2022-03-31
2021-03-31
2020-03-31
2019-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Canopy Growth has not reported any payouts.
  • Unable to verify if Canopy Growth's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Canopy Growth's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Canopy Growth has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Canopy Growth's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Canopy Growth afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Canopy Growth has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

WEED Management

 What is the CEO of Canopy Growth's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bruce Linton
COMPENSATION CA$2,516,014
AGE 51
TENURE AS CEO 0.7 years
CEO Bio

Mr. Bruce A. Linton, BPA serves as Chief Executive Officer and Chairman at Canopy Rivers Inc. and serves its Director since April 2017 and served as Acting Chief Executive Officer. Mr. Linton is a Co-Founder of Canopy Growth Corporation (formerly Tweed Marijuana Inc) and has been its Co-Chief Executive Officer since August 28, 2014. Mr. Linton serves as the Chief Executive Officer and President for Clearford's two divisions: the Wastewater Systems Division and the Brooklin Concrete Division. He also served as the Chief Executive Officer and President at Martello Technologies, Inc. He has been Vice President of SC Stormont Inc., since January 2005. He served as Interim Chief Executive Officer of Canopy Growth Corporation (formerly Tweed Marijuana Inc). from August 2014 to February 2015. He served as the Chief Executive Officer of Clearford Industries Inc. (now known as Clearford Water Systems Inc.) from February 28, 2005 to December 31, 2012 and served as its President from February 28, 2005 to May 28, 2012. He served as Chief Executive Officer and President of Brooklin Concrete Products Limited. He served as the Chief Executive Officer of IWSSI. He served as the President of Clearford Industries from August 2009 to May 28, 2012. He was Re-Founder of Computerland.ca., and served as its General Manager from April 2002 to December 2004. He Co-founded webHancer Corp. in 1999 and served as its President and Chief Executive Officer. He has more than 10 years of senior executive experience in technology based companies, including Crosskeys Systems Corp. He has significant and recent experience with the introduction of both CrossKeys and Clearford to the Asia Pacific region. He has established regular engagement with the World Bank and Asia Development Bank while focused on markets in India, Philippines, China, Peru, Colombia, Ecuador, Azerbaijan and Uzbekistan. He lead CrossKeys and Clearford's entry into the China market and in 2009 Clearford was awarded by the Canada-China Business Council for their market entry strategy. He was part of the leadership team for the Nasdaq/TSX IPO at CrossKeys Systems Corporation. He served as a Director of Asia Pacific Operations, Director of Business Relations and Director of Finance and Administration of CrossKeys. He serves as the Chairman of Canopy Growth Corporation (formerly Tweed Marijuana Inc) and Co-Chairman of Martello Technologies Group Inc. since August 15, 2018 and serves as its Director since April 29, 2013. He serves as a Director of and Bedrocan Cannabis Corp. He has been a Non-Executive Director of TW Holdings Limited since June 1, 2016. He serves as a Director of Carleton University and is Treasurer and Director at the non-profit youth organization Canadian World Youth. He served as a Director of Thermal Energy International Inc. since October 25, 2012 until November 28, 2016. He served as a Director of Clearford Industries Inc. from August 22, 2006 to October 16, 2013. He served as Director of Marchwell Ventures Ltd. from September 12, 2000 to November 17, 2011. He served as Director of Brooklin Concrete Products Limited. He was an industry liaison for Newbridge in 1992. He sits as Canada's representative on the World Bank's Water Sanitation Program Advisory Council as well as sitting on the Cleantech Advisory Board for Foreign Affairs Canada. He was Chairman of the Ottawa Community Loan Foundation, Board of Governor for Carleton University. He served as the President of the Nepean Skating Club and past-President of the Carleton University Students Association. He holds Bachelors of Public Administration from Carleton University (1986-1992).

CEO Compensation
  • Bruce's compensation has increased whilst company is loss making.
  • Bruce's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Canopy Growth management team in years:

1.1
Average Tenure
  • The average tenure for the Canopy Growth management team is less than 2 years, this suggests a new team.
Management Team

Bruce Linton

TITLE
Co-Founder
COMPENSATION
CA$3M
AGE
51
TENURE
0.7 yrs

Mark Anthony Zekulin

TITLE
President & Co-CEO
COMPENSATION
CA$2M
TENURE
0.7 yrs

Timothy Saunders

TITLE
Executive VP & CFO
COMPENSATION
CA$2M
TENURE
3.7 yrs

Rade Kovacevic

TITLE
Executive Vice President
COMPENSATION
CA$2M
TENURE
1.3 yrs

Ann Gordon

TITLE
Vice President of Corporate Finance

Peter Popplewell

TITLE
Chief Technology Officer
TENURE
1.1 yrs

Ru Wadasinghe

TITLE
Chief Information Officer

Tom Shipley

TITLE
Senior VP of Global Quality Assurance & Chief Science Officer

phil Shaer

TITLE
Chief Legal Officer & VP of Human Resources

Jordan Sinclair

TITLE
Director of Communications
Board of Directors Tenure

Average tenure and age of the Canopy Growth board of directors in years:

0.3
Average Tenure
56.5
Average Age
  • The average tenure for the Canopy Growth board of directors is less than 3 years, this suggests a new board.
Board of Directors

Marc Wayne

TITLE
Founding President & Director of Canopy Health Innovations
COMPENSATION
CA$331K
AGE
52
TENURE
2.2 yrs

Peter Stringham

TITLE
Director
COMPENSATION
CA$161K
AGE
68
TENURE
2.4 yrs

Bruce Linton

TITLE
Co-Founder
COMPENSATION
CA$3M
AGE
51

John Bell

TITLE
Lead Director
COMPENSATION
CA$271K
AGE
71

Bill Newlands

TITLE
Director
AGE
59
TENURE
0.3 yrs

David Klein

TITLE
Director
AGE
54
TENURE
0.3 yrs

Judy Schmeling

TITLE
Director
AGE
58
TENURE
0.3 yrs

Robert Hanson

TITLE
Director
AGE
55
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Canopy Growth insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
13. Dec 18 Buy David Bigioni Individual 12. Dec 18 12. Dec 18 252 CA$42.82 CA$10,791
11. Dec 18 Buy David Bigioni Individual 10. Dec 18 10. Dec 18 3,600 CA$41.99 CA$151,164
11. Dec 18 Sell Robert Hanson Individual 06. Dec 18 06. Dec 18 -5 CA$29.85 CA$-149
03. Oct 18 Sell Murray Goldman Individual 28. Sep 18 28. Sep 18 -70,000 CA$64.28 CA$-4,499,600
03. Oct 18 Sell Mark Anthony Zekulin Individual 27. Sep 18 27. Sep 18 -358,334 CA$64.70 CA$-23,182,562
02. Oct 18 Sell Murray Goldman Individual 28. Sep 18 28. Sep 18 -300,000 CA$65.74 CA$-19,532,431
02. Oct 18 Sell HBAM Holdings Inc Company 27. Sep 18 27. Sep 18 -307,845 CA$64.66 CA$-19,900,788
02. Oct 18 Sell Onbelay Capital Inc. Company 27. Sep 18 27. Sep 18 -48,683 CA$64.07 CA$-3,119,120
02. Oct 18 Sell John Bell Individual 27. Sep 18 27. Sep 18 -36,350 CA$64.43 CA$-2,342,030
29. Sep 18 Sell Christopher Schnarr Individual 27. Sep 18 27. Sep 18 -107,868 CA$65.44 CA$-7,058,882
04. Jul 18 Sell Murray Goldman Individual 29. Jun 18 29. Jun 18 -100,000 CA$38.63 CA$-3,823,062
X
Management checks
We assess Canopy Growth's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Canopy Growth has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

WEED News

Simply Wall St News

What Kind Of Shareholders Own Canopy Growth Corporation (TSE:WEED)?

Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Companies of this size are usually well known to retail investors, too.

Simply Wall St -

What You Must Know About Canopy Growth Corporation's (TSE:WEED) Financial Health

Mid-caps stocks, like Canopy Growth Corporation (TSE:WEED) with a market capitalization of CA$8.32b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. … Today we will look at WEED’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Check out our latest analysis for Canopy Growth

Simply Wall St -

Canopy Growth Corporation's (TSE:WEED) Path To Profitability

I’ve put together a brief outline of industry analyst expectations for WEED, its year of breakeven and its implied growth rate. … View our latest analysis for Canopy Growth According to the industry analysts covering WEED, breakeven is near. … How fast will WEED have to grow each year in order to reach the breakeven point by 2020?

Simply Wall St -

Does Canopy Growth Corporation's (TSE:WEED) Debt Level Pose A Problem?

See our latest analysis for Canopy Growth Does WEED generate an acceptable amount of cash through operations? … With this growth in debt, WEED's cash and short-term investments stands at CA$101.80M , ready to deploy into the business. … I suggest you continue to research Canopy Growth to get a more holistic view of the stock by looking at: Future Outlook: What are well-informed industry analysts predicting for WEED’s future growth?

Simply Wall St -

What Does Canopy Growth Corporation's (TSE:WEED) Share Price Indicate?

I find that Canopy Growth’s ratio of 8.2x is trading slightly above its industry peers’ ratio of 6.96x, which means if you buy Canopy Growth today, you’d be paying a relatively reasonable price for it. … And if you believe that Canopy Growth should be trading at this level in the long run, there’s only an insignificant downside when the price falls to its real value. … Given that Canopy Growth’s share is fairly volatile (i.e.

Simply Wall St -

Top TSX Growth Stocks To Buy

Investors seeking to increase their exposure to growth should consider companies such as Canopy Growth and Sangoma Technologies. … TSX:WEED Future Profit Jan 2nd 18 Sangoma Technologies Corporation (TSXV:STC) Sangoma Technologies Corporation develops, manufactures, distributes, and supports voice and data connectivity components for software-based communication applications worldwide. … TSXV:ICC Future Profit Jan 2nd 18 For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.

Simply Wall St -

Best Growth Stocks To Buy Now

Individual investors like stocks with a high growth potential. … TOS is expected to deliver an extremely high earnings growth over the next couple of years of 56.41%, bolstered by a significant revenue which is expected to more than double. … TSX:TOS Future Profit Nov 22nd 17 For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.

Simply Wall St -

Is Canopy Growth Corporation (TSX:WEED) As Financially Strong As Its Balance Sheet Indicates?

Check out our latest analysis for Canopy Growth Is WEED’s level of debt at an acceptable level? … To assess this, I compare WEED's cash and other liquid assets against its upcoming debt. … Our analysis shows that WEED does have enough liquid assets on hand to meet its upcoming liabilities, which lowers our concerns should adverse events arise.

Simply Wall St -

WEED Company Info

Map
Description

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Details
Name: Canopy Growth Corporation
WEED
Exchange: TSX
Founded:
CA$20,379,253,497
343,027,327
Website: http://www.canopygrowth.com
Address: Canopy Growth Corporation
1 Hershey Drive,
Smiths Falls,
Ontario, K7A 0A8,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX WEED Common Shares The Toronto Stock Exchange CA CAD 27. Mar 2014
NYSE CGC Common Shares New York Stock Exchange US USD 27. Mar 2014
DB 11L1 Common Shares Deutsche Boerse AG DE EUR 27. Mar 2014
LSE 0UO9 Common Shares London Stock Exchange GB CAD 27. Mar 2014
Number of employees
Current staff
Staff numbers
2,700
Canopy Growth employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/22 00:35
End of day share price update: 2019/02/21 00:00
Last estimates confirmation: 2019/02/21
Last earnings filing: 2019/02/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.